These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25807853)

  • 1. Renal allograft re-use and herpetic re-infection.
    Setyapranata S; Holt SG; Wiggins KJ; Mulley WR; Kerr PG; Landgren AJ; Eisen DP; Young A; Opdam H; Robertson A; Asadi K; Hughes PD
    Nephrology (Carlton); 2015 Mar; 20 Suppl 1():17-21. PubMed ID: 25807853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes simplex virus-2 transmission following solid organ transplantation: Donor-derived infection and transplantation from prior organ recipients.
    Macesic N; Abbott IJ; Kaye M; Druce J; Glanville AR; Gow PJ; Hughes PD; Korman TM; Mulley WR; O'Connell PJ; Opdam H; Paraskeva M; Pitman MC; Setyapranata S; Rawlinson WD; Johnson PDR
    Transpl Infect Dis; 2017 Oct; 19(5):. PubMed ID: 28618165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor derived HSV hepatitis in a kidney transplant recipient leading to liver fibrosis and portal hypertension.
    Shaw BI; Nanavati AJ; Taylor V; Miller RA; Kappus M; Barbas AS
    Transpl Infect Dis; 2019 Feb; 21(1):e13029. PubMed ID: 30431215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe cytomegalovirus infection in a second kidney transplant recipient treated with ganciclovir, leflunomide, and immunoglobulins, with complications including seizures, acute HCV infection, drug-induced pancytopenia, diabetes, cholangitis, and multi-organ failure with fatal outcome: a case report.
    Miszewska-Szyszkowska D; Mikołajczyk N; Komuda-Leszek E; Wieczorek-Godlewska R; Świder R; Dęborska-Materkowska D; Szmidt J; Durlik M
    Ann Transplant; 2015 Mar; 20():169-74. PubMed ID: 25813912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fulminant hepatitis following primary herpes simplex virus infection.
    Al Midani A; Pinney J; Field N; Atkinson C; Haque T; Harber M
    Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):107-11. PubMed ID: 21196623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal HSV-2 primary infection most likely acquired by kidney transplantation: A case report.
    Truffot A; Noble J; Dartevel A; Chevalier E; Dard C; Giovannini D; Andreani J; Burrel S; Boutolleau D; Epaulard O; Pavese P; Morand P; Lupo J; Germi R
    Int J Antimicrob Agents; 2023 May; 61(5):106769. PubMed ID: 36870404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes simplex virus type 1 hepatitis due to primary infection in a pancreas-kidney transplant recipient.
    Feugeas J; Mory S; Jeulin H; Velay A; Pertek JP; Ladriere M; Losser MR
    J Clin Virol; 2016 Jul; 80():57-9. PubMed ID: 27155056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The transmission of donor-derived malignant melanoma to a renal allograft recipient.
    Milton CA; Barbara J; Cooper J; Rao M; Russell C; Russ G
    Clin Transplant; 2006; 20(5):547-50. PubMed ID: 16968479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
    Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
    Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
    Harvala H; Stewart C; Muller K; Burns S; Marson L; MacGilchrist A; Johannessen I
    J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
    Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated herpes simplex type-2 (HSV-2) infection after solid-organ transplantation.
    Basse G; Mengelle C; Kamar N; Ribes D; Selves J; Cointault O; Suc B; Rostaing L
    Infection; 2008 Feb; 36(1):62-4. PubMed ID: 18165863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
    Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
    Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients.
    Helanterä I; Lautenschlager I; Koskinen P
    Nephrol Dial Transplant; 2009 Jan; 24(1):316-20. PubMed ID: 18842670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir].
    Guirado L; Rabella N; Díaz JM; Facundo C; Maderuelo A; Margall N; Silva I; García-Maset R; Calabia J; Giménez I; Garra N; Solà R; Ballarín JA
    Nefrologia; 2008; 28(3):293-300. PubMed ID: 18590496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.